FibroGen Reports First Quarter 2018 Financial Results
May 09, 2018 16:02 ET
|
FibroGen, Inc
Pamrevlumab Data to be Presented at ATS 2018 and ASCO 2018 Roxadustat U.S. Phase 3 Clinical Studies on Track to Readout in Fourth Quarter 2018Conference Call Today at 5:00 p.m. Eastern Time/2:00...
FibroGen Announces Pamrevlumab Oral and Poster Presentations at European Respiratory Society International Congress 2017
September 05, 2017 16:05 ET
|
FibroGen, Inc.
SAN FRANCISCO, Sept. 05, 2017 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, today announced oral and poster presentations on pamrevlumab, an anti-CTGF...
aTyr Pharma Announces Second Quarter 2017 Operating Results and Provides an Update on Innovative Immunology Pipeline
August 14, 2017 16:05 ET
|
aTyr Pharma Inc.
– Resolaris Demonstrated Favorable Safety Profile in Rare Muscular Dystrophy Patients in Extension Studies –– iMod.Fc Program for Interstitial Lung Disease (ILD) on Track to Commence Phase 1 Clinical...
FibroGen Announces Positive Topline Results from Phase 2 Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis
August 07, 2017 16:50 ET
|
FibroGen, Inc.
Meets Primary Endpoint with Statistical Significance Management to discuss results on today’s quarterly financial results conference call SAN FRANCISCO, Aug. 07, 2017 (GLOBE NEWSWIRE) -- FibroGen,...
FibroGen Reports Second Quarter 2017 Financial Results
August 07, 2017 16:38 ET
|
FibroGen, Inc.
Company Announces Positive Topline Results from Phase 2 Study in IPF Conference Call and Webcast to be Held Today at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time SAN FRANCISCO, Aug. 07, 2017 ...
FibroGen Reports Fiscal 2016 Financial Results
March 01, 2017 16:02 ET
|
FibroGen, Inc.
SAN FRANCISCO, March 01, 2017 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, today reported financial results for the year ended December 31, 2016, and...
FibroGen to Report Second Quarter 2016 Financial Results on August 8, 2016
August 02, 2016 20:00 ET
|
FibroGen, Inc.
SAN FRANCISCO, Aug. 02, 2016 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a research-based biopharmaceutical company focused on the discovery, development, and commercialization of novel...
FibroGen Announces Receipt of $62 Million License Payment from AstraZeneca
July 08, 2016 04:00 ET
|
FibroGen, Inc.
SAN FRANCISCO, July 08, 2016 (GLOBE NEWSWIRE) -- FibroGen, Inc. (Nasdaq:FGEN) (“FibroGen”), a research-based biopharmaceutical company, announced today that it has received a scheduled $62 million...
FibroGen to Present at the Goldman Sachs 37th Annual Global Healthcare Conference
June 06, 2016 07:00 ET
|
FibroGen, Inc.
SAN FRANCISCO, June 06, 2016 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), announced that Chief Executive Officer, Thomas B. Neff, will be presenting at the Goldman Sachs 37th Annual Global...
FibroGen Reports Financial Results for the First Quarter of 2016
May 09, 2016 16:02 ET
|
FibroGen, Inc.
Continued Progress in Roxadustat Phase 3 Studies; Promising Interim Pancreatic Cancer Data –Webcast Conference Call Scheduled for 4:30pm EST Today– SAN FRANCISCO, May 09, 2016 (GLOBE NEWSWIRE)...